(Q43903326)

27 November 2017

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial (English)

1 reference

27 November 2017

1 reference

Sung Chul Hwang

9

0 references

Richard G. Wunderink

object named as

Richard G Wunderink

1

0 references

Xavier Wittebole

12

object named as

Xavier Wittebole

1 reference

27 November 2017

18

Steven Opal

1 reference

27 November 2017

Pierre-François Laterre

2

1 reference

27 November 2017

Bruno Francois

3

1 reference

27 November 2017

Dominique Perrotin

4

1 reference

27 November 2017

Antonio Artigas

5

1 reference

27 November 2017

Luis Otero Vidal

6

1 reference

27 November 2017

Suzana M Lobo

7

1 reference

27 November 2017

Jorge San Juan

8

1 reference

27 November 2017

Thierry Dugernier

10

1 reference

27 November 2017

Steven LaRosa

11

1 reference

27 November 2017

Jean-Francois Dhainaut

13

1 reference

27 November 2017

Christopher Doig

14

1 reference

27 November 2017

Meryl H Mendelson

15

1 reference

27 November 2017

Christian Zwingelstein

16

1 reference

27 November 2017

Guoqin Su

17

1 reference

27 November 2017

CAPTIVATE Trial Group

19

1 reference

27 November 2017

language of work or name

English

0 references

publication date

4 February 2011

1 reference

American Journal of Respiratory and Critical Care Medicine

27 November 2017

1 reference

27 November 2017

183

1 reference

27 November 2017

11

1 reference

27 November 2017

1561-1568

1 reference

Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.

27 November 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Management of Community-acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Microvascular thrombosis and multiple organ dysfunction syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Inflammation and coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Does disseminated intravascular coagulation lead to multiple organ failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Cell biology of tissue factor, the principal initiator of blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Bidirectional relation between inflammation and coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Blockade of tissue factor: treatment for organ injury in established sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Multiplicity and flexibility in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Adjunctive therapy in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201007-1167OC

10.1164/RCCM.201007-1167OC

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference